scholarly journals Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options

Cancer ◽  
2013 ◽  
Vol 120 (6) ◽  
pp. 781-789 ◽  
Author(s):  
Sanjiv S. Agarwala ◽  
Alexander M. M. Eggermont ◽  
Steven O'Day ◽  
Jonathan S. Zager
Keyword(s):  
Metastatic Melanoma ◽  
Therapeutic Options ◽  
Comprehensive Review

Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: A comprehensive review study

2020 ◽  
Author(s):  
Masoumeh Roohaninasab ◽  
Parvin Mansouri ◽  
Farnoosh Seirafianpour ◽  
Ali Jamshidi Naeini ◽  
Azadeh Goodarzi
Keyword(s):  
Therapeutic Options ◽  
Special Focus ◽  
Comprehensive Review ◽  
Review Study

scholarly journals Post-Operative Adhesions: A Comprehensive Review of Mechanisms

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 867
Author(s):  
Ali Fatehi Hassanabad ◽  
Anna N. Zarzycki ◽  
Kristina Jeon ◽  
Justin F. Deniset ◽  
Paul W. M. Fedak
Keyword(s):  
Clinical Trials ◽  
Healthcare Costs ◽  
Adhesion Formation ◽  
Therapeutic Options ◽  
Preclinical Research ◽  
Safety And Efficacy ◽  
Comprehensive Review ◽  
Surgical Adhesions ◽  
Consistent Basis ◽  
Almost All

Post-surgical adhesions are common in almost all surgical areas and are associated with significant rates of morbidity, mortality, and increased healthcare costs, especially when a patient requires repeat operative interventions. Many groups have studied the mechanisms driving post-surgical adhesion formation. Despite continued advancements, we are yet to identify a prevailing mechanism. It is highly likely that post-operative adhesions have a multifactorial etiology. This complex pathophysiology, coupled with our incomplete understanding of the underlying pathways, has resulted in therapeutic options that have failed to demonstrate safety and efficacy on a consistent basis. The translation of findings from basic and preclinical research into robust clinical trials has also remained elusive. Herein, we present and contextualize the latest findings surrounding mechanisms that have been implicated in post-surgical adhesion formation.

scholarly journals Analysis of Survival at Metastatic Melanoma Patients Treated with Vemurafenib - a Three Year Single Institution Study

2018 ◽  
Vol 49 (2) ◽  
Author(s):  
Zdenka Gojković ◽  
Dejan Đokanović ◽  
Branislava Jakovljević ◽  
Siniša Maksimović ◽  
Saša Jungić ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Prognostic Marker ◽  
Braf Inhibitor ◽  
Therapeutic Options ◽  
Single Institution ◽  
Number Of Patients ◽  
Clinical Centre ◽  
Melanoma Patients ◽  
The Republic

Introduction: The introduction of BRAF inhibitor vemurafenib significantly improvedoverall survival (OS) in metastatic melanoma patients.Aim of the Study: The purpose of this study was to determine OS and progressionfree survival (PFS) in patients with advanced metastatic melanoma treated withvemurafenib in the Oncology Clinic, University Clinical Centre of the Republic ofSrpska (UKC RS). The secondary goal is to determine the effect of elevated serumlactate dehydrogenase (LDH) on OS.Patients and Methods: We analysed patients that received vemurafenib in theApril 2015. until March 2018. They had pathohistologically confirmed B-RAF positivemetastatic melanoma. LDH values were measured at the start of the treatment.Results: A total of 16 patients were analyzed, with an average age of 53 years(37-78). A large number of patients at the start had multiple sites of metastases.Calculated OS in patients who received vemurafenib is 11.8 months (p=0,23), withstandard deviation (SD) 9.18. The calculated PFS is 9.5, SD 7,57. OS in patients withnormal LDH is 14.4 months, SD 10.73, and with elevated LDH is 8.4 months, SD4.9 (p=0.079).Conclusion: Use of vemurafenib resulted in an improvement in PFS, with improvedOS in patients with advanced BRAF-mutated melanoma. In patients with elevatedLDH OS was reduced. This shows that LDH is a good prognostic marker and thatwe should do it routinely for all patients with melanoma. This study has indicatedthe need for new diagnostic and therapeutic options for melanoma in Republic ofSrpska.

scholarly journals A comprehensive review of COVID-19 treatment

2021 ◽  
Vol 38 (2) ◽  
pp. 105-115
Author(s):  
Zeinab Afshar ◽  
Arefeh Babazadeh ◽  
Mostafa Javanian ◽  
Mohammad Barary ◽  
Vasigala Rekha ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Global Health ◽  
Clinical Efficacy ◽  
Virus Strain ◽  
Therapeutic Options ◽  
Plasma Transfusion ◽  
Comprehensive Review ◽  
Health Threat ◽  
Novel Coronavirus

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.

scholarly journals Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Gérald E. Piérard ◽  
François Aubin ◽  
Philippe Humbert
Keyword(s):  
Monoclonal Antibody ◽  
Overall Survival ◽  
T Cells ◽  
Skin Cancer ◽  
Malignant Melanoma ◽  
Adverse Effects ◽  
Metastatic Melanoma ◽  
Cytotoxic T Cells ◽  
Therapeutic Options ◽  
Life Threatening

Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.

scholarly journals CDK4/6 Inhibitors in Melanoma: A Comprehensive Review

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1334
Author(s):  
Mattia Garutti ◽  
Giada Targato ◽  
Silvia Buriolla ◽  
Lorenza Palmero ◽  
Alessandro Marco Minisini ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Drug Development ◽  
Metastatic Melanoma ◽  
Genetic Background ◽  
Preliminary Evidence ◽  
Active Compounds ◽  
Comprehensive Review ◽  
Mek Inhibitors ◽  
Recent Advances

Historically, metastatic melanoma was considered a highly lethal disease. However, recent advances in drug development have allowed a significative improvement in prognosis. In particular, BRAF/MEK inhibitors and anti-PD1 antibodies have completely revolutionized the management of this disease. Nonetheless, not all patients derive a benefit or a durable benefit from these therapies. To overtake this challenges, new clinically active compounds are being tested in the context of clinical trials. CDK4/6 inhibitors are drugs already available in clinical practice and preliminary evidence showed a promising activity also in melanoma. Herein we review the available literature to depict a comprehensive landscape about CDK4/6 inhibitors in melanoma. We present the molecular and genetic background that might justify the usage of these drugs, the preclinical evidence, the clinical available data, and the most promising ongoing clinical trials.

Sign in / Sign up

Export Citation Format

Share Document